20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.
115 citations
,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” This article reviews how different 5alpha-reductase and 3alpha-HSD enzymes impact androgen levels and highlights their potential as drug targets for androgen-related diseases, but provides no new experimental findings.
196 citations
,
May 2001 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that SZ95 sebocytes and HaCaT keratinocytes exhibit distinct enzyme expressions and activities, implicating their different roles in androgen metabolism and homeostasis in vitro.
18 citations
,
March 2020 in “Frontiers in Neuroendocrinology” This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.
12 citations
,
February 2016 in “Biochemical and Biophysical Research Communications” This study found that sulforaphane treatment enhanced hair regeneration in ob/ob mice by increasing DHT-degrading enzyme levels and lowering plasma testosterone and DHT.